Recent 8-K filings for TENX

• July 2, 2026, 8:00 AM ET other material materiality 0.65 neutral item 8.01item 9.01

  Tenax Therapeutics to present Phase 3 LEVEL trial results at ESC Congress 2026; topline data expected in August

  Phase 3 LEVEL trial results to be presented in Late-Breaking Clinical Science session at ESC Congress 2026 (Aug 28-31, Munich).

• March 10, 2026, 7:59 PM ET other material materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases ×2

  Tenax Therapeutics reports Q4/FY2025 loss; LEVEL study fully enrolled, topline Q3 2026

  Achieved 230-patient randomization target in Phase 3 LEVEL study; topline data expected Q3 2026.

• December 17, 2025, 6:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  Tenax Therapeutics confirms LEVEL Phase 3 trial enrollment on track; initiates global LEVEL-2 study

  Blinded Sample Size Re-estimation (BSSR) shows LEVEL is powered >90% to detect 25m change in 6MWD primary endpoint.

• September 16, 2025, 7:59 PM ET regulatory materiality 0.75 positive item 8.01item 9.01

  Tenax Therapeutics receives EPO intention to grant patent for levosimendan in PH-HFpEF through 2040

  EPO intends to grant patent covering TNX-103 (oral levosimendan) and other formulations for PH-HFpEF.

• September 9, 2025, 7:59 PM ET other material materiality 0.80 positive item 1.01item 9.01

  Tenax Therapeutics expands levosimendan license to exclusive worldwide oral rights; gains manufacturing rights

  Amendment with Orion grants Tenax exclusive worldwide rights to develop, commercialize, and manufacture oral levosimendan products.

• August 13, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Tenax Therapeutics reports Q2 net loss of $10.9M; Phase 3 LEVEL study enrollment on track for H1 2026

  Net loss of $10.9M in Q2 2025 vs $3.6M in Q2 2024; R&D spend $6.1M, G&A $5.7M.

• May 14, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Tenax Therapeutics Q1 net loss $10.4M; Phase 3 LEVEL enrollment on track for year-end 2025

  Net loss $10.4M in Q1 2025 vs $3.8M in Q1 2024; company is a development-stage biotech with no revenue.

• March 25, 2025, 7:59 PM ET earnings materiality 0.80 neutral item 2.02item 9.01

  Tenax Therapeutics reports FY2024 net loss of $17.6M; $94.9M cash; raised $125M for TNX-103 Phase 3 trials

  Net loss for FY2024 was $17.6M vs $7.7M in 2023; Q4 net loss $6.3M vs $3.2M.

• March 6, 2025, 6:59 PM ET other material materiality 0.75 positive item 1.01item 3.02item 8.01item 9.01

  Tenax raises $25M, expands Phase 3 LEVEL study to 230 patients, adds LEVEL-2 trial

  Private placement with RTW Investments grossed ~$25M; issued 378K shares + pre-funded warrants for 3.76M shares at $6.04/$6.03.

• November 13, 2024, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Tenax Therapeutics Q3 net loss $4.0M; raised $100M private placement

  Net loss of $4.0M for Q3 2024 vs $2.0M in Q3 2023; R&D expenses $3.1M (up from $1.1M).

• October 30, 2024, 7:59 PM ET other material materiality 0.65 negative item 5.02item 5.07item 9.01

  Stockholders approve 7.9M share increase in 2022 Stock Incentive Plan

  Approved Amendment No. 2 to 2022 Stock Incentive Plan, increasing authorized shares to 8,336,600 (7,935,912 new shares).

• August 13, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Tenax Therapeutics reports Q2 net loss of $3.6M, cash $9.4M; raised $100M

  Net loss of $3.6M ($1.83/sh) vs loss of $1.1M ($4.00/sh) in Q2 2023.

• August 12, 2024, 7:59 PM ET other material materiality 0.75 positive item 7.01item 9.01

  Tenax Therapeutics closes $100M private placement to fund Phase 3 levosimendan program

  Gross proceeds of ~$100M from oversubscribed private placement led by BVF Partners.

• August 6, 2024, 7:59 PM ET other material materiality 0.85 positive item 1.01item 3.02item 8.01item 9.01

  Tenax Therapeutics Raises $100M in Oversubscribed Private Placement Led by BVF Partners

  Gross proceeds ~$100M from 1.45M shares, 31.9M pre-funded warrants, and 16.7M warrants at $3.00/share (warrant strike $4.50).

• June 13, 2024, 7:59 PM ET leadership materiality 0.60 neutral item 5.02item 5.07item 9.01

  Tenax Therapeutics expands equity pool by 400k shares; CMO shifts to part-time

  Stockholders approved Amendment No. 1 to 2022 Stock Incentive Plan, increasing authorized shares to 400,688.

• May 14, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01 ◈ Earnings Releases

  Tenax Therapeutics Q1 net loss widens to $3.8M; Phase 3 LEVEL study enrolling

  Net loss of $3.8M vs $1.4M in Q1 2023; R&D expenses rose to $2.7M from $0.3M.

• February 23, 2024, 6:59 PM ET regulatory materiality 0.60 positive item 8.01

  Tenax Therapeutics regains Nasdaq minimum float compliance; deficiency closed

  Received Nasdaq notice on Feb 22, 2024 confirming over 500,000 publicly held shares.

• February 20, 2024, 6:59 PM ET other material materiality 0.70 positive item 1.01item 9.01 ◈ Material Agreements

  Tenax Therapeutics expands levosimendan license to worldwide rights from Orion

  Amendment expands Tenax's exclusive global rights to levosimendan for PH-HFpEF from North America to worldwide.

• February 12, 2024, 6:59 PM ET other material materiality 0.65 neutral item 1.01item 8.01item 9.01 ◈ Material Agreements ×3

  Tenax Therapeutics prices $9M public offering of common stock and warrants

  1.6M shares or pre-funded warrants plus 3.2M common warrants at $5.65/unit.

• February 8, 2024, 6:59 PM ET other material materiality 0.65 positive item 8.01item 9.01

  Tenax Therapeutics enrolls first patient in Phase 3 LEVEL study for TNX-103 in PH-HFpEF; topline data expected H2 2025

  First patient enrolled in Phase 3 LEVEL study of oral TNX-103 (levosimendan) for PH-HFpEF; 152-patient trial.

• February 6, 2024, 6:59 PM ET other material materiality 0.65 positive item 8.01item 9.01

  USPTO allows patent covering levosimendan use in PH-HFpEF through 2040

  USPTO Notice of Allowance for patent covering oral (TNX-103), IV, subcutaneous levosimendan, active metabolites, and drug combos for PH-HFpEF.

• January 19, 2024, 6:59 PM ET other material materiality 0.75 positive item 8.01

  Tenax Therapeutics regains compliance with Nasdaq minimum bid price rule

  Received Nasdaq written confirmation on Jan 18, 2024, after 10 consecutive trading days (Jan 3-17) closing at $1.00 or greater.

• January 12, 2024, 6:59 PM ET regulatory materiality 0.75 negative item 3.01item 5.02item 9.01 ◈ executive_change ×2◈ Listing & Compliance Notices

  Tenax Therapeutics receives Nasdaq delisting notice; appoints interim CFO Lawrence Hoffman

  Nasdaq notified Tenax on Jan 11, 2024 that it fails minimum 500,000 publicly held shares after 1-for-80 reverse split.

• December 1, 2023, 6:59 PM ET other material materiality 0.60 neutral item 5.07 ◈ Shareholder Votes ×2

  Tenax Therapeutics shareholders approve reverse stock split authorization

  Reverse split ratio range 1:10 to 1:80, exact ratio set by board; authorized until Nov 30, 2024.

• November 13, 2023, 6:59 PM ET regulatory materiality 0.85 positive item 8.01item 9.01

  FDA clears IND for Tenax's TNX-103 (oral levosimendan) for PH-HFpEF; Phase 3 LEVEL study to start Q4 2023

  FDA cleared IND for TNX-103 (oral levosimendan) to treat PH-HFpEF, enabling Phase 3 LEVEL study in Q4 2023.

• July 19, 2023, 7:59 PM ET regulatory materiality 0.70 positive item 8.01item 9.01

  Tenax Therapeutics receives U.S. patent for oral levosimendan (TNX-103) in PH-HFpEF, expiring 2040

  USPTO granted Patent No. 11,701,355 for oral levosimendan (TNX-103) to treat PH-HFpEF, with exclusivity through December 2040.

• May 31, 2023, 7:59 PM ET regulatory materiality 0.75 positive item 8.01item 9.01

  Tenax Therapeutics receives USPTO Notice of Allowance for oral levosimendan patent in PH-HFpEF

  Patent covers oral levosimendan (TNX-103) for PH-HFpEF; term through Dec 2040, possible extension beyond.

• April 13, 2023, 7:59 PM ET other material materiality 0.60 neutral item 8.01item 9.01

  Tenax prioritizes oral levosimendan Phase 3 for PH-HFpEF in 2023

  Company to initiate Phase 3 trial of TNX-103 (oral levosimendan) for PH-HFpEF in 2023.

• March 30, 2023, 7:59 PM ET regulatory materiality 0.65 negative item 3.01 ◈ Listing & Compliance Notices

  Tenax Therapeutics receives Nasdaq bid price deficiency notice; 180 days to regain compliance

  Nasdaq notified Tenax on March 29, 2023 that bid price closed below $1.00 for 30 consecutive business days.

• March 22, 2023, 7:59 PM ET other material materiality 0.65 positive item 8.01item 9.01

  Tenax Therapeutics receives US patent for IV levosimendan in PH-HFpEF, expiring Dec 2040

  U.S. Patent No. 11,607,412 covers IV levosimendan for pulmonary hypertension with HFpEF.

• February 7, 2023, 6:59 PM ET other material materiality 0.60 neutral item 1.01item 8.01item 9.01 ◈ Material Agreements ×2

  Tenax Therapeutics raises ~$15.6M in public offering of common stock and warrants

  Priced 8,666,666 shares (or pre-funded warrants) plus 17,333,332 warrants at $1.80/unit.

• February 1, 2023, 6:59 PM ET regulatory materiality 0.70 positive item 8.01item 9.01

  Tenax Therapeutics granted US patent covering IV levosimendan for PH-HFpEF until 2040

  USPTO Notice of Allowance for patent covering IV levosimendan in PH-HFpEF; patent expected to last until 2040.

• October 11, 2022, 7:59 PM ET other material materiality 0.65 positive item 8.01item 9.01

  Tenax Therapeutics announces positive oral levosimendan data in PH-HFpEF patients at HFSA meeting

  18 PH-HFpEF patients transitioned from IV to oral levosimendan with no serious adverse events reported.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.65 · Most common event other_material

21 positive 5 negative 24 neutral

source · TENX on sec.gov